Subtype
Esophageal Adenocarcinoma
CI-CAN-00005190Explore in graph →
70 active trials2 approved drugs2 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005190Explore in graph →
Clinical trials
181 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (27)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02606396 | Cryotherapy for Malignant Dysphagia in Patients With Advanced Esophageal Cancer | completed | N/A | 15 | Hunter Holmes Mcguire Veteran Affairs Medical CenterFED | 1 | Apr 14, 2026 | clinicaltrials |
| NCT05051475 | Endoscopic Radiofrequency Ablation Versus Hybrid Argon Plasma Coagulation in the Treatment of Barrett's Esophagus(RATE) | completed | N/A | 62 | Centre of Postgraduate Medical EducationOTHER | 1 | Oct 3, 2025 |
| clinicaltrials |
| NCT06030180 | CLUE: CLinical Utility Study of EsoGuard(PR-0410) | completed | N/A | 566 | Lucid Diagnostics, Inc.INDUSTRY | 1 | Jun 27, 2025 | clinicaltrials |
| NCT03429816 | OPPOSITE: Outcome Prediction of Systemic Treatment in Esophagogastric Carcinoma(OPPOSITE) | completed | N/A | 120 | University Hospital HeidelbergOTHER | 1 | Mar 27, 2025 | clinicaltrials |
| NCT05069766 | Preoperative Marking of the Oral Resection Margin in Esophageal Cancer With a Surgical Fiducial Marker - First Experiences | completed | N/A | 10 | Rigshospitalet, DenmarkOTHER | 1 | Feb 23, 2024 | clinicaltrials |
| NCT04293458 | Efficacy of EsoGuard on Samples Collected Using EsoCheck Versus EGD for the Diagnosis of BE(ESOGUARDBE1) | completed | N/A | 145 | Lucid Diagnostics, Inc.INDUSTRY | 2 | Jan 25, 2023 | clinicaltrials |
| NCT02513784 | Trial to Assess the Effects of an Antimicrobial Mouthwash on the Esophageal Microbiome(Mouthwash) | completed | N/A | 20 | Columbia UniversityOTHER | 1 | Sep 22, 2022 | clinicaltrials |
| NCT04669951 | Urokinase-type Plasminogen Activator Receptor and Gastroesophageal Cancer | completed | N/A | 100 | Michael Patrick AchiamOTHER | 1 | Jun 3, 2021 | clinicaltrials |
| NCT02890979 | Swallowable Sponge Cell Sampling Device and Next Generation Sequencing in Detecting Esophageal Cancer in Patients With Low or High Grade Dysplasia, Barrett Esophagus, or Gastroesophageal Reflux Disease | completed | N/A | 11 | OHSU Knight Cancer InstituteOTHER | 1 | Nov 25, 2020 | clinicaltrials |
| NCT02100189 | Esophageal Cytology With FISH in Detecting Esophageal Cancer | completed | N/A | 50 | OHSU Knight Cancer InstituteOTHER | 1 | May 11, 2017 | clinicaltrials |
| NCT02610764 | Pilot Sudy: Resectable Esophageal Adenocarcinoma and the Relevance of CTC(ESO-CTC) | completed | N/A | 19 | University Hospital FreiburgOTHER | 1 | Apr 13, 2017 | clinicaltrials |
| NCT01871636 | ESD Versus EMR for Treatment of Early Barrett's Adenocarcinoma | completed | N/A | 40 | Evangelisches Krankenhaus DüsseldorfOTHER | 1 | Sep 9, 2015 | clinicaltrials |
Data updated 22 days agoSource updated Apr 14, 2026source: clinicaltrials